Ripertamab for chronic inflammatory demyelinating polyneuropathy (CIDP)
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a new drug called Ripertamab for people with CIDP, a nerve condition causing weakness. The study will see if it can improve symptoms compared to standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and diagnosed with CIDP (a nerve condition).
- Your CIDP needs to be causing at least moderate disability, like trouble walking or using your hands.
- You can be on low-dose steroids or IVIg and willing to stop, have never been treated, or have stopped treatment at least 6 months ago.
- You cannot have other nerve diseases that explain your symptoms, or certain other serious health problems.
- You must not be pregnant or breastfeeding, and you must use effective birth control during and 90 days after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ripeltumab in people with neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation of the optic nerve and spinal cord. It aims to reduce relapses by targeting the immune system.
This trial tests a drug called rituximab to see if it can help people with chronic inflammatory demyelinating polyneuropathy (CIDP) achieve remission. It may offer a new treatment option for those who are newly diagnosed or who are on maintenance therapy with wear-off symptoms or failed withdrawal attempts.
This trial tests whether a new medication called riliprubart works as well as the usual IVIg treatment for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It may offer another option for managing your condition.
This trial tests a new medicine called Ripertamab to see if it can help children and young adults with nephrotic syndrome who keep relapsing or need steroids to stay in remission. It aims to offer a treatment option that may reduce relapses.
This study tests a new medicine called Empasiprubart for adults with ongoing CIDP. It aims to see if fewer symptoms return and if it can replace current treatments.
This trial tests nipocalimab (an antibody medicine) to improve symptoms and control activity in chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disease that causes weakness and numbness. It may help reduce disease activity and disability, while checking safety.
Hear when a new Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.